VILAS Ventures Invests in $13.5M Series A3 Round for CND Life Sciences to Advance Neurodegenerative Diagnostics
VILAS Ventures, a healthcare-focused investment firm, announced its participation in the recent $13.5M Series A3 equity financing for CND Life Sciences, and reasons for supporting CND’s mission.
“Neurodegenerative diseases remain among the most urgent unmet needs in medicine,” said Daniel Livschutz, Managing Partner at VILAS Ventures. “CND’s Syn-One Test® combines cutting-edge pathology and AI to provide objective diagnostic clarity for clinicians.”
Livschutz added, “This investment is also personal. A family member endured years of misdiagnosis before receiving a Parkinson’s diagnosis. Earlier access to objective testing like Syn-One could have significantly improved their journey.”
The funding, which includes investment from other new and longtime investors, will accelerate CND’s commercial growth and R&D initiatives and expand access to the Syn-One Test—the first commercially available skin-based diagnostic that visualizes and quantifies abnormal alpha-synuclein, a key marker of synucleinopathies such as Parkinson’s disease.
Learn more about the Syn-One Test
